---
title: DNTT-mediated DNA Damage Response Drives Inotuzumab Ozogamicin Resistance in
  B-cell Acute Lymphoblastic Leukemia
date: '2025-01-10'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39791601/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20250110170836&v=2.18.0.post9+e462414
source: Blood
description: Inotuzumab Ozogamicin (InO) is an antibody-calicheamicin conjugate with
  striking efficacy in B-cell acute lymphoblastic leukemia (B-ALL). However, there
  is wide inter-patient variability in treatment response, and the genetic basis of
  this variation remains largely unknown. Using a genome-wide CRISPR screen, we discovered
  the loss of DNTT as a primary driver of InO resistance. Mechanistically, DNTT downregulation
  attenuated InO-induced DNA damage response, cell cycle arrest, and ...
disable_comments: true
---
Inotuzumab Ozogamicin (InO) is an antibody-calicheamicin conjugate with striking efficacy in B-cell acute lymphoblastic leukemia (B-ALL). However, there is wide inter-patient variability in treatment response, and the genetic basis of this variation remains largely unknown. Using a genome-wide CRISPR screen, we discovered the loss of DNTT as a primary driver of InO resistance. Mechanistically, DNTT downregulation attenuated InO-induced DNA damage response, cell cycle arrest, and ...